Consensus Relmada Therapeutics, Inc.

Stocks

RLMD

US75955J4022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:26:10 22/09/2026 +04			5-day change	1st Jan Change
4.200 ^USD	+0.96%		-5.41%	-13.04%

09-11	Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each	MT
09-08	Relmada Therapeutics, Inc. Announces Resignation of Raj S. Pruthi as Chief Medical Officer Urology, Effective September 3, 2026	CI

Evolution of the Average Target: Relmada Therapeutics, Inc.

Evolution of the Target Price: Relmada Therapeutics, Inc.

Changes in Analyst Recommendations: Relmada Therapeutics, Inc.

60.Qdr0WuRJXYSw_vagCIMheaLAUjyacJV4uGbotWKMTZY.E6ymPo05bNDYzZ-WQsJpP-eFH0z7JNsLzxKbwgzjDP8U7oAi1BZo7PqIuw~14ae1c098cc4ddc5a4f1860ef3c57b04

Analysts' recommendations: Relmada Therapeutics, Inc.

06-18	HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target	MT
03-24	Piper Sandler Initiates Coverage on Relmada Therapeutics With Overweight Rating	MT
11-19	Mizuho Upgrades Relmada Therapeutics to Outperform From Neutral	MT
11-06	Relmada Therapeutics Insider Bought Shares Worth $299,200, According to a Recent SEC Filing	MT
11-04	Relmada gets FDA support for two registrational study paths for NDV-01 in non-muscle invasive bladder cancer	RE
11-04	Relmada Therapeutics, Inc. Announces Fda Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder Cancer	CI
05/12/24	Mizuho Downgrades Relmada Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $23	MT
04/12/24	Leerink Partners Downgrades Relmada Therapeutics to Market Perform From Outperform, $1 Price Target; Shares Plummet	MT
17/09/24	Jefferies Upgrades Relmada Therapeutics to Buy From Hold, Price Target is $13	MT
05/06/24	Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target	MT
23/01/23	SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating	MT
09/12/22	Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target	MT
14/10/22	Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81	MT
14/10/22	Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy	MT
13/10/22	Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90	MT
13/10/22	Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64	MT
23/09/22	Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating	MT
06/09/22	Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating	MT
12/08/22	Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating	MT
09/05/22	Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating	MT
24/03/22	Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating	MT
20/12/21	SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating	MT
18/11/21	Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target	MT
27/07/21	Relmada Therapeutics : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RELMADA THERAPEUTICS, INC.					+158.41%
	WUXI APPTEC CO., LTD.					+11.38%
	ARGENX SE					+18.24%
	WUXI BIOLOGICS (CAYMAN) INC.					+9.7%
	INSMED INCORPORATED					+64.91%
	BIONTECH SE					+21.18%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+21.5%
	EXELIXIS, INC.					-6.17%
	SUMMIT THERAPEUTICS INC.					+72.15%
	Average					+37.99%
	Weighted average by Cap.					+21.29%